Tag
Comprehensive plasma proteomics reveal three molecular subtypes of transthyretin cardiac amyloidosis linked to distinct prognoses and differential tafamidis treatment responses, highlighting personalized therapeutic opportunities.
The HELIOS-B trial showed vutrisiran improves survival and cardiac outcomes in transthyretin amyloidosis with cardiomyopathy, with consistent benefits regardless of baseline tafamidis use, supporting further evaluation of combination therap
In a multinational registry of patients with concomitant aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR‑CA), both ATTR‑specific therapy (predominantly tafamidis) and aortic valve replacement (AVR) were independently associ
